We are live on
!
Find out more
BC
Broadfin Capital Portfolio holdings
AUM
$747M
1-Year Est. Return
100.56%
This Fund
S&P 500
This Quarter
Est. Return
+20.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$460M
AUM Growth
-$24.7M
(-5.1%)
Cap. Flow
-$63.4M
Cap. Flow
% of AUM
-13.79%
Top 10 Holdings %
Top 10 Hldgs %
55.03%
Holding
52
New
9
Increased
6
Reduced
21
Closed
13
Top Buys
| 1 |
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$24.2M |
| 2 |
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
|
+$16.9M |
| 3 |
AGN
Allergan plc
AGN
|
+$15.9M |
| 4 |
SIEN
Sientra, Inc.
SIEN
|
+$10.1M |
| 5 |
Heron Therapeutics
HRTX
|
+$8.99M |
Top Sells
| 1 |
Iovance Biotherapeutics
IOVA
|
+$41.7M |
| 2 |
Catalyst Pharmaceutical
CPRX
|
+$13.4M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$12.2M |
| 4 |
ADMS
Adamas Pharmaceuticals
ADMS
|
+$11.7M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$11.5M |
Sector Composition
| 1 | Healthcare | 78.06% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Iovance Biotherapeutics
IOVA
$2.23B
| $38.2M | 8.32% |
1,559,299
-2,769,004
| -64% | -$41.7M |
|
|
PETX
2
DELISTED
Aratana Therapeutics, Inc.
PETX
| $37.5M | 8.15% |
7,258,135
| – | – |
|
|
NVRO
3
DELISTED
NEVRO CORP.
NVRO
| $31.7M | 6.89% |
488,265
-134,350
| -22% | -$8.37M |
|
|
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $29.6M | 6.45% |
676,879
+429,979
| +174% | +$24.2M |
|
5
Travere Therapeutics
TVTX
$5.27B
| $21.2M | 4.6% |
1,053,314
+37,200
| +4% | +$734K |
|
|
MRTX
6
CALL
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $20.6M | 4.48% |
+200,000
| New | +$15.6M |
|
|
BDSI
7
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $19.9M | 4.33% |
4,281,943
-93,123
| -2% | -$434K |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $19.2M | 4.18% |
+114,804
| New | +$15.9M |
|
|
EIGR
9
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $17.6M | 3.82% |
55,205
+48,762
| +757% | +$16.9M |
|
|
BHVN
10
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $17.5M | 3.81% |
+400,000
| New | +$22.5M |
|
|
GBT
11
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $16.7M | 3.62% |
316,619
-78,690
| -20% | -$4.52M |
|
|
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
| $16.5M | 3.58% |
344,762
-26,936
| -7% | -$1.08M |
|
|
SCTL
13
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $15.9M | 3.46% |
1,741,203
-388,441
| -18% | -$3.11M |
|
|
14
Heron Therapeutics
HRTX
$89.1M
| $12.2M | 2.66% |
657,998
+450,000
| +216% | +$8.99M |
|
|
15
Catalyst Pharmaceutical
CPRX
| $10.6M | 2.31% |
2,765,070
-3,091,928
| -53% | -$13.4M |
|
|
16
PUT
Travere Therapeutics
TVTX
$5.27B
| $10M | 2.19% |
+500,000
| New | +$9.87M |
|
17
DexCom
DXCM
$29.6B
| $9.48M | 2.06% |
253,200
-16,800
| -6% | -$528K |
|
|
AVDL
18
DELISTED
Avadel Pharmaceuticals
AVDL
| $8.97M | 1.95% |
3,102,673
| – | – |
|
|
SIEN
19
DELISTED
Sientra, Inc.
SIEN
| $8.62M | 1.88% |
+140,000
| New | +$10.1M |
|
|
LJPC
20
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $8.25M | 1.79% |
891,760
-1,103,151
| -55% | -$8.31M |
|
|
SSKN
21
DELISTED
Strata Skin Sciences
SSKN
| $8.11M | 1.76% |
325,662
+39,030
| +14% | +$974K |
|
|
SBBP
22
DELISTED
Strongbridge Biopharma plc.
SBBP
| $7.96M | 1.73% |
2,544,839
-247,210
| -9% | -$908K |
|
|
VRAY
23
DELISTED
ViewRay, Inc.
VRAY
| $7.63M | 1.66% |
866,500
| – | – |
|
24
Sol-Gel Technologies
SLGL
$272M
| $6.65M | 1.45% |
73,010
-11,760
| -14% | -$938K |
|
25
SI-BONE Inc
SIBN
$771M
| $6.36M | 1.38% |
+312,898
| New | +$5.37M |
|
Similar funds
CBU
CONA
MP
SC
KGACF
BPWA
TRAM
VMI
Broadfin Capital's Q2 2019 Portfolio in Review
As of Q2 2019, Broadfin Capital held 52 positions worth $460M, down 5.1% from $484M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Broadfin Capital withdrew a net $63.4M in Q2 2019, closing 13 positions and reducing 21 holdings. Its most notable exit was Aclaris Therapeutics, an estimated $12.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier.
Against the trend, Broadfin Capital opened a new position in Allergan plc worth $19.2M.
- Broadfin Capital's largest Q2 2019 buy was Allergan plc: 114,804 shares worth $19.2M.
- Broadfin Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $24.2M increase.
- Broadfin Capital's biggest Q2 2019 reduction was Iovance Biotherapeutics, cutting an estimated $41.7M.
- Broadfin Capital fully exited Aclaris Therapeutics in Q2 2019, selling an estimated $12.2M.
- Broadfin Capital's ten largest holdings make up 55% of its $460M portfolio in Q2 2019.
- Broadfin Capital opened 9 new positions and closed 13 in Q2 2019.
- Broadfin Capital's portfolio value fell 5.1% quarter-over-quarter to $460M.
Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.